Pfizer's Other Operating Expense for the
three
months ended in Mar. 2026 was MXN21,333 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was MXN88,717 Mil.
Pfizer's quarterly Other Operating Expense
declined
from Sep. 2025 (MXN22,435 Mil) to Dec. 2025 (MXN22,147 Mil) and
declined
from Dec. 2025 (MXN22,147 Mil) to Mar. 2026 (MXN21,333 Mil).
Pfizer's annual Other Operating Expense
increased
from Dec. 2023 (MXN80,339 Mil) to Dec. 2024 (MXN110,243 Mil) but then
declined
from Dec. 2024 (MXN110,243 Mil) to Dec. 2025 (MXN87,760 Mil).
Pfizer Other Operating Expense Related Terms
Pfizer Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Pfizer's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN88,717 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of MXN88,717 Mil mean?
Pfizer (MEX:PFE) has a Other Operating Expense of MXN88,717 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Pfizer and its competitors.
Is Pfizer's Other Operating Expense too high?
Pfizer's current Other Operating Expense is MXN88,717 Mil. Overall, Pfizer has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Other Operating Expense compare to GILD and BMY?
Pfizer's Other Operating Expense of MXN88,717 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Pfizer and its competitors. Pfizer's current Other Operating Expense is MXN88,717 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (MEX:PFE) is currently considered Fairly Valued. The stock's GF Value™ is MXN456.50, compared to a current price of MXN423.06 — trading 7.3% below its estimated fair value. The current Other Operating Expense is MXN88,717 Mil. Pfizer's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Pfizer (MEX:PFE), the current Other Operating Expense is MXN88,717 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pfizer (MEX:PFE) Overvalued in 2026?
Based on GuruFocus' analysis, Pfizer stock appears to be undervalued.
The current stock price of MXN423.06 is trading 7.3% below its estimated GF Value™ of MXN456.50.
GuruFocus considers Pfizer to be Fairly Valued.
Key valuation signals for MEX:PFE:
Other Operating Expense: MXN88,717 Mil
GF Value™: MXN456.50 vs. price of MXN423.06 (7.3% below fair value)
No single metric tells the full story. See the MEX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
67GF Score
Get the complete analysis for MEX:PFE
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PFE has been successfully added to your 
